353 related articles for article (PubMed ID: 16322085)
41. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
Yazici Y; Shi N; John A
Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
[TBL] [Abstract][Full Text] [Related]
42. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
Maetzel A; Bombardier C; Strand V; Tugwell P; Wells G
J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426
[TBL] [Abstract][Full Text] [Related]
43. Leflunomide in Pakistani patients with rheumatoid arthritis: prospective study in daily rheumatology practice.
Ahmad NM; Farman S; Saeed MA; Hameed R; Umair M; Ghafoor E
Int J Rheum Dis; 2011 Feb; 14(1):48-54. PubMed ID: 21303481
[TBL] [Abstract][Full Text] [Related]
44. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
[TBL] [Abstract][Full Text] [Related]
45. Factors associated with permanent work disability in Mexican patients with rheumatoid arthritis. A case-control study.
Morales-Romero J; Gonzalez-Lopez L; Celis A; Rodriguez-Arreola BE; Cabrera-Pivaral CE; Gamez-Nava JI
J Rheumatol; 2006 Jul; 33(7):1247-9. PubMed ID: 16758509
[TBL] [Abstract][Full Text] [Related]
46. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent.
Hjardem E; Hetland ML; Østergaard M; Krogh NS; Kvien TK;
Ann Rheum Dis; 2005 Aug; 64(8):1220-3. PubMed ID: 15640272
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.
Kapral T; Stamm T; Machold KP; Montag K; Smolen JS; Aletaha D
Arthritis Res Ther; 2006; 8(2):R46. PubMed ID: 16507172
[TBL] [Abstract][Full Text] [Related]
48. Prevalence and management of rheumatoid arthritis in the general population of Greece--the ESORDIG study.
Andrianakos A; Trontzas P; Christoyannis F; Kaskani E; Nikolia Z; Tavaniotou E; Georgountzos A; Krachtis P;
Rheumatology (Oxford); 2006 Dec; 45(12):1549-54. PubMed ID: 16690763
[TBL] [Abstract][Full Text] [Related]
49. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
Blomqvist P; Feltelius N; Ekbom A; Klareskog L
J Rheumatol; 2000 May; 27(5):1171-7. PubMed ID: 10813283
[TBL] [Abstract][Full Text] [Related]
50. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR
Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
[TBL] [Abstract][Full Text] [Related]
51. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
52. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Verschueren P; Esselens G; Westhovens R
Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
[TBL] [Abstract][Full Text] [Related]
53. Time to consultation and disease-modifying antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta perspective.
Nanji JA; Choi M; Ferrari R; Lyddell C; Russell AS
J Rheumatol; 2012 Apr; 39(4):707-11. PubMed ID: 22337235
[TBL] [Abstract][Full Text] [Related]
54. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
Söderlin MK; Lindroth Y; Jacobsson LT
Rheumatology (Oxford); 2007 Aug; 46(8):1355-8. PubMed ID: 17567634
[TBL] [Abstract][Full Text] [Related]
55. Antirheumatic drug use and the risk of acute myocardial infarction.
Suissa S; Bernatsky S; Hudson M
Arthritis Rheum; 2006 Aug; 55(4):531-6. PubMed ID: 16874796
[TBL] [Abstract][Full Text] [Related]
56. Gaps in care for rheumatoid arthritis: a population study.
Lacaille D; Anis AH; Guh DP; Esdaile JM
Arthritis Rheum; 2005 Apr; 53(2):241-8. PubMed ID: 15818655
[TBL] [Abstract][Full Text] [Related]
57. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs.
Wong M; Mulherin D
Musculoskeletal Care; 2007 Sep; 5(3):148-59. PubMed ID: 17590885
[TBL] [Abstract][Full Text] [Related]
58. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
59. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective.
Widdifield J; Bernatsky S; Paterson JM; Thorne JC; Cividino A; Pope J; Gunraj N; Bombardier C
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):53-7. PubMed ID: 20806274
[TBL] [Abstract][Full Text] [Related]
60. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified?
Rajakulendran S; Gadsby K; Deighton C
Musculoskeletal Care; 2008 Dec; 6(4):233-45. PubMed ID: 18702106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
